Challenging the norm: Epicutaneous immunotherapy for canine atopic dermatitis.

This article discusses a clinical trial that explores the use of epicutaneous immunotherapy (EPIT) as a potential treatment for canine atopic dermatitis (cAD), a common allergic skin disease in dogs. The study aimed to assess the feasibility, effectiveness, and safety of EPIT in dogs with cAD over a six-month period. The results showed that EPIT effectively improved the dogs' clinical condition, with significant reductions in pruritus (itching), skin lesions, and improvements in quality of life. The study also found that EPIT was well-tolerated and safe, with a high adherence rate among dog owners. This pilot study suggests that EPIT could be a promising and practical treatment option for cAD in dogs, warranting further investigation. [Extracted from the article]